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Determination of residual renal function with iohexol clearance in
hemodialysis patients. Residual renal function (RRF) may contribute
significantly to the total dialysis prescription. Conventional quantitation of
RRF in hemodialysis (HD) patients is measured by urea clearance and
requires a 24-hour urine collection which is often difficult to perform and
inaccurate. The renal clearance of iohexol was evaluated as an alternative
method for RRF assessment (iohexol-derived RRF) in hemodialysis
patients. An intravenous bolus of iohexol (12 ml; 300 mg iodine/mi) was
administered to 42 hemodialysis patients following routine HD. A single
blood sample was obtained approximately 44 hours later (pre-HD) to
determine the plasma clearance of iohexol using x-ray fluorescence
methods. Total body clearance of iohexol (TBj) and non-renal clearance
of iohexol (CNejo) 2.87 0.3 mI/mm (mean SCM) were used to calculate
iohexol-derived RRF CNRIO). lohexol-derived RRF determina-
tions were then compared to urea clearance-derived RRF measurements.
The RRF contribution to the dialysis prescription was also calculated
utilizing iohexol-derived RRF compared to urea-derived RRF. lohexol-
derived RRF did not differ from urea-derived RRF (2.48 0.3 vs. 2.64
0.4 mI/mm, P = 0.21). The RRF contribution to the weekly dialysis
prescription (Kt/V) did not differ when iohexol-derived RRF was com-
pared to urea-derived RRF (0.94 0.1 vs. 0.93 0.1, P = 0.9).
Additionally, the effect of iohexol on RRF was assessed in 17 HD patients.
Urea-derived RRF determinations one week after iohexol exposure did
not differ from those measured one week prior to iohexol exposure (3.17
0.6 vs. 2.91 0.5 mI/mm, respectively). Thus, renal clearance of iohexol
can be an accurate and safe measure of RRF in HD patients and
potentially simplify delivery of the dialysis prescription.
Residual renal function (RRF) in patients undergoing dialytic
therapy can provide a significant portion of the total dialysis
prescription, particularly during the first six to twelve months of
dialytic treatment. Conventionally, determination of the glomer-
ular filtration rate in hemodialysis patients utilizes urea clearance
but requires a 24-hour urine collection which is difficult for many
patients to perform and often inaccurate. Ideally, a method to
quantitate residual renal function would involve clearance of an
easily administered, non-nephrotoxic and non-radiolabeled sub-
stance, require a single blood sample, be independent of timed
urine collections, and an accurate measure of glomerular filtra-
tion. Clearance of iohexol, a non-ionic iodinated contrast agent,
has demonstrated high correlation with clearances of conven-
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tional markers of glomerular filtration rate such as inulin, 99mTc
DTPA, and 51Cr-EDTA [1—61.
A series of studies were undertaken to determine if plasma
clearance of iohexol could be used to assess residual renal
function in hemodialysis patients. Plasma clearance of iohexol was
compared to renal clearance of iohexol as well as conventional,
urea-based quantitation of residual renal function. If residual
renal function as measured by plasma clearance of iohexol were
accurate, would the contribution of residual renal function to the
total dialysis prescription differ when compared to urea-derived
residual renal function determinations? Lastly, studies were un-
dertaken to determine whether iohexol exposure results in neph-
rotoxic injury in individuals with markedly reduced renal function,
specifically, those with residual renal function receiving hemodia-
lytic therapy.
Methods
Subjects
The disposition of iohexol (Sanofi Winthrop Pharmaceuticals,
NY, USA) was determined in 42 subjects receiving chronic,
outpatient, hemodialytic therapy (mean age 60, range 23 to 83
years). Nine anephric subjects and 33 subjects with residual renal
function were included in the study after giving written informed
consent. The study protocol was reviewed and approved by the
investigators' Institutional Review Board. All subjects received
their routine hemodialysis treatments via SPS I500 dialysis
machines (Baxter Renal Division, McGraw Park, IL, USA) uti-
lizing cellulose acetate membranes, with a surface area of 2.1 m2
and ultrafiltration coefficient of 10.6 mI/hr/mm Hg (Baxter Renal
Division), an average blood flow rate of 450 ml/min, and dialysate
flow rate of 700 ml/min. Duration of dialysis treatments ranged
from 2.5 to 3.5 hours, and conventional intravenous heparin
anticoagulation was used during hemodialysis.
Clinical parameters
The following parameters of iohexol disposition were deter-
mined: total body clearance of iohexol (plasma clearance; G1-,);
non-renal clearance of iohexol in anephric patients;
CNRO); renal clearance of iohexol (CRO); lohexol-derived RRF;
urea-derived RRF; iohexol-derived Kt/V; and urea-derived Kt/V.
Patients received an intravenous bolus dose of 12 ml iohexol
(300 mg of iodine/mi) through the venous limb of their arterio-
venous fistula, following a routine outpatient hemodialysis treat-
ment. Blood and urine samples were obtained for iodine and urea
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concentration determinations 24 and 44 hours post-injection and
were used to calculate renal clearance of iohexol and urea, CTB0
was calculated from the rate of disappearance of iodine from the
plasma using x-ray fluorescence techniques. The CNRIO in 9
anephric patients was equal to their CrBj, determinations, while
in the 33 patients with RRF, CNRO was the difference between
CTBO and CRIO. A single blood sample method (44-hr plasma
iodine concentration) for estimating plasma clearance of iohexol
was correlated with the multi-sample ("2-point") method to
determine whether single-sample determinations of plasma io-
hexol clearance could be utilized to determine iohexoi disposition
in HD patients.
lohexol-derived RRF was defined as single-sample CTBIO minus
CNRIO. Urea-derived RRF determinations were based on renal
clearance of urea calculated from conventional formulae using
timed urine collections and blood sampling for urea concentra-
tions as outlined above for iohexol renal clearance.
The RRF contribution to the weekly Kt/V was calculated
utilizing both iohexol-derived RRF and urea-derived RRF and
compared.
Potential nephrotoxicity of iohexol was assessed in 17 of the 33
patients with RRF. Urea-derived RRF determinations were per-
formed on a weekly basis prior to iohexol exposure (Week 1),
concomitant with iohexol exposure (Week 2), and following
iohexol exposure (Week 3) to determine if significant changes
occurred following iohexol administration.
Analytical methods
Serum and urine iodine concentrations were measured using
x-ray fluorescence methods (Renalyzer PRX90, Provalid AB,
Lund, Sweden) with a lower limit of detection of 0.009 mg/mi. The
inter-assay coefficients of variation for Renalyzer iodine determi-
nations were 4.4% and 1.6% for the low (0.1 mg/mI) and high (0.4
mg/mI) iodine concentration ranges, respectively. The intra-assay
coefficients of variation for Renalyzer iodine determinations were
6.2% and 1.7% for the low (0.1 mg/mI) and high (0.4 mg/mI)
iodine concentration ranges, respectively.
The following equation was used to calculate renal clearance of
iohexol:
AR
CR,0 =
where AR is the amount of iodine recovered in the urine for the
interval 0 to 44 hours and AUC is the area under the plasma
iodine concentration-time curve for that interval. CTBO was
calculated from the rate of disappearance of iodine from the
plasma according to the following equation:
Dose
Craio = AUC
where dose is the amount of iodine (mg) infused and AUC is the
area under the plasma iodine concentration-time curve for the
intervals 0 to 24 and 24 to 44 hours. Single-point CTBIQ was
calculated using the following equation according to Jacobsson
[71:
(se sample) = +0.0016 X th(Q0Nd X C 1)
lohexol clearance (mi/mm) area-derived
Fig. 1. Comparison between single-point (44 hr sample) and multi-sample,
area-derived iohexol clearance, r2 = 0.94.
where Q01 is the total amount of iodine injected (mg), t is the
interval between iohexol infusion and blood sampling (approxi-
mately 2,640 mm or 44 hr), C is the iodine concentration (mg/mi)
in the blood sample obtained at time t, and V is the volume of
distribution (ml) of iohexol. Non-renal clearance of iohexol
(CNRIO) was calculated as follows:
Cp,j0 = Cr — CRO
CNRI,) in the 9 anephric patients equalled their CTBIOdetermi-
nations.
Calculation of the RRF contribution to the total weekly dialysis
prescription (Kt/V) utilizes the following equation:
Urea clearance (mi/mm) X 10080 (min/wk)
Total body water (ml)
Statistical analysis
Statistical analysis included linear regression, analysis of vari-
ance (ANOVA), and paired t-testing and utilized the Statistical
Package for the Social Sciences (SPSS 6.1 for Windows, Chicago,
IL, USA). All values are expressed as means SEM unless
otherwise indicated. Statistical significance was assumed for P
values < 0.05.
Results
Figure 1 demonstrates the high correlation, r2 = 0.94, found
between single point and multiple sample CTBIO determinations.
Single-point C1, was 5.90 0.4 mI/mm in patients with RRF
(Table 1). This differed significantly from iohexol-derived RRF,
2.48 0.3 and urea-derived RRF, 2.64 0.4, as well as from
CTBK, (or CNRIO) in anephric patients, 2.87 0.3 ml/min. lohexol-
derived RRF (2.48 0.3) and urea-derived RRF (2.64 0.4
mi/mm) did not significantly differ, P = 0.21.
The RRF contribution to the weekly dialysis prescription
(Kt/V) was calculated utilizing both iohexol-derived RRF and
urea-derived RRF. lohexol-derived Kt/V, 0.94 0.1, did not
differ from urea-derived Kt/V, 0.93 0.1 (Table 1).
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Anephric (N = 9) RRF (N =33)
TBCLIO mi/mm 2.87 0.3 5.90 0.4
RRTO mI/mm — 2.48 0.3
RRF=. mt/mm — 2.64 0.4
kT/Vk, - 0.94 0.1
kT/V=ca — 0.93 0.1
In the 17 patients who performed serial urine collections for
urea-derived RRF determinations before and after iohexol expo-
sure (Fig. 2), urea-derived RRF did not differ between Week 1
(2.91 0.5), Week 2-iohexol administration (2.83 0.7), and
Week 3 (3.2 0.6 mI/mm).
Discussion
A method to quantify glomerular filtration which is accurate,
efficient, and safe continues to elude clinicians. Serum creatinine
values are crude markers of renal function, at best, and are
affected by a number of non-renal factors as well as tubular
secretion. Creatinine clearances as well as inulin clearances
involving timed urine collections and blood sampling are tedious,
difficult for patients to perform, and impractical for routine
use. Various radionuclide markers including 99"Tc-DTPA,
EDTA, and 1251-iothalamate, have been used as reliable measures
of glomerular filtration but are costly, involve special handling of
samples, and involve radiation exposure. Plasma "decay" or
disappearance of iohexol was first reported by O'Reilly, Brooman
and Martin [8] to represent a new method for measuring glomer-
ular filtration. In 1991, data supporting replacement of inulin
clearance with iohexol clearance as the new gold standard for
glomerular filtration quantitation were published [9]. Numerous
investigators have subsequently reported iohexol clearance to be a
safe and accurate measure of renal function, but all such reports
have involved non-dialysis subjects with glomerular filtration rates
covering a broad range [2, 8, 10—141.
To out knowledge, this represents the first published report
assessing the accuracy and safety of plasma iohexol clearance
being used to quantify residual renal function in hemodialysis
patients by comparison to renal clearance of iohexol as well as
conventional, urea-based determinations. Total body clearance of
iohexol, CTB,,, was measured using both multi-sample (24 and 44
hr plasma iodine concentrations) as well as single-sample (44 hr)
methods and found to be highly correlative (r2 = 0.94). The
correlation, however, between single-sample CTB,, in patients
with residual renal function versus renal clearance of iohexol as
well as C,,, in anephric patients was relatively low. The fact that
plasma iohexol clearance occurred in anephric patients (approx-
imately 3 ml/min) indicated non-renal clearance of iohexol.
Subsequently, we observed that a similar degree of non-renal
clearance of iohexol occurred in hemodialysis patients with uri-
nary output, accounting for the significant difference between
CTBO and iohexol-derived RRF as well as urea-derived RRF
values. Thus, when non-renal clearance of iohexol is taken into
account, iohexol-derived RRF, urea-derived RRF, and renal
clearance of iohexol do not differ, which supports the hypothesis
that plasma clearance of iohexol is an accurate measure of
residual renal function. Although non-renal clearance of iohexol
I
.
.
.
I I
.
jf
i I
Week 1 Week 2 Week 3
oh exo I
Fig. 2. Urea-derived RRF values (mean SEM) in 17 LID patients with
urina?y output one week prior to (2.9? 0.5), during (2.83 0.7), and
week Jhllowing iohexol exposure (3.2 0.6 mI/mm) demonstrating
decrement in residual renal Jhnction (P > 0.05 for all groups, ANOVA).
would not be considered significant in individuals with normal or
relatively normal renal function, its significance readily becomes
apparent when total glomerular filtration is markedly reduced.
Determination of residual renal function is important as it may
contribute significantly to the overall dialysis prescription. Once it
was established that single-sample, plasma iohexol clearance was
an accurate measure of glomerular filtration in hemodialysis
patients, we determined whether the contribution of residual
renal function to the total dialysis prescription differed when
urea-derived versus iohexol-derived clearances were used. No
difference between iohexol-derived Kt/V and urea-derived KtIV
values was observed. Simplifying quantitation of residual renal
function may, in turn, simplify delivery of the hemodialysis
component of the overall prescription.
Lastly, potential nephrotoxicity of iohexol in patients with very
low glomerular filtration rates was probed. Serial urine collections
were performed by 17 of our subjects (those willing to collect 3
timed collections over a 3-week period) one week prior to, during,
and one week following iohexol exposure. We found no decre-
ment in urea-derived residual renal function over the three-week
period particularly during week 3 when contrast-induced renal
injury would have been evident. Thus, we conclude that a single,
small volume dose of non-ionic iohexol poses no nephrotoxic risk
to hemodialysis patients with residual renal function.
In conclusion, iohexol clearance can be used safely, accurately,
and efficiently for quantitation of residual renal function as long as
its non-renal clearance is taken into account in patients undergo-
ing hemodialytic therapy. Such methods preclude multiple blood
sampling, timed urine collections, and exposure to radiolabeled
compounds. Further studies using iohexol clearance are war-
ranted in settings of acute non-oliguric renal failure requiring
dialytic support as well as in peritoneal dialysis patients who
maintain residual renal function.
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